P/E ratio for Haemonetics (HAE)
P/E ratio as of October 2023 (TTM): 32.4
According to Haemonetics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 32.4017. At the end of 2021 the company had a P/E ratio of 123.
P/E ratio history for Haemonetics from 2001 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2021 | 123 | |
| 2018 | 112 | -165.46% |
| 2017 | -171 | -234.9% |
| 2016 | 127 | -486.28% |
| 2015 | -32.8 | -150.98% |
| 2014 | 64.3 | 11.03% |
| 2013 | 57.9 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 31.2 | -3.57% | 🇺🇸 USA |
 Medtronic MDT | 28.1 | -13.15% | 🇮🇪 Ireland |
 Thermo Fisher Scientific TMO | 33.9 | 4.75% | 🇺🇸 USA |
 Baxter BAX | -6.50 | -120.06% | 🇺🇸 USA |
 Becton Dickinson BDX | 46.6 | 43.97% | 🇺🇸 USA |
 Stryker Corporation SYK | 37.2 | 14.76% | 🇺🇸 USA |
 PerkinElmer
PKI | 15.0 | -53.81% | 🇺🇸 USA |
 Cerus CERS | -5.14 | -115.86% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.